Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DOD Biotech PCLBKK:DOD-R -5.84%67 EV-to-Revenue is 0.74 as of Sep. 05, 2026, which is 78% below its 10-year median of 3.33. GuruFocus rates BKK:DOD-R with a GF Score™ of 67/100 and a GF Value™ of ฿1.52. The stock has 6 warning signs investors should review. Among 1,961 Consumer Packaged Goods companies, DOD Biotech PCL ranks better than 65.94% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, DOD Biotech PCL's enterprise value is ฿390.7 Mil.
DOD Biotech PCL's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ฿529.1 Mil. Therefore, DOD Biotech PCL's EV-to-Revenue for today is 0.74.
The historical rank and industry rank for DOD Biotech PCL's EV-to-Revenue or its related term are showing as below:
BKK:DOD-R'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.55 Med: 3.33 Max: 12.56
Current: 0.74
During the past 12 years, the highest EV-to-Revenue of DOD Biotech PCL was 12.56. The lowest was 0.55. And the median was 3.33.
BKK:DOD-R's EV-to-Revenue is ranked better than 65.94% of 1961
companies
in the Consumer Packaged Goods industry
Industry Median: 1.08
vs BKK:DOD-R: 0.74
As of today (2026-09-05), DOD Biotech PCL's stock price is ฿0.96667.
DOD Biotech PCL's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ฿1.16. Therefore, DOD Biotech PCL's PS Ratio for today is 0.83.
DOD Biotech PCL's share price for today is ฿0.96667.
DOD Biotech PCL's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿1.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOD Biotech PCL EV-to-Revenue Related Terms
DOD Biotech PCL EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for DOD Biotech PCL's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, DOD Biotech PCL's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DOD Biotech PCL EV-to-Revenue vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where DOD Biotech PCL's EV-to-Revenue falls into.
DOD Biotech PCL's current Enterprise Value is ฿390.7 Mil.
DOD Biotech PCL's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿529.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOD Biotech PCL (BKK:DOD-R) has a EV-to-Revenue of 0.74 as of Sep. 05, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on DOD Biotech PCL and its competitors. This is 78% below median its historical median of 3.33. Over the past decade, DOD Biotech PCL's EV-to-Revenue has ranged from 0.55 to 12.56. According to the industry distribution chart, DOD Biotech PCL ranks #668 out of 1961 companies in the Consumer Packaged Goods industry, placing it in the top 34.1%.
Is DOD Biotech PCL's EV-to-Revenue too high?
DOD Biotech PCL's current EV-to-Revenue of 0.74 is 78% below median its 10-year median of 3.33. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 12.56. The Consumer Packaged Goods industry median EV-to-Revenue is 1.08. DOD Biotech PCL's value of 0.74 is 31.5% below this industry median. Based on the distribution chart, DOD Biotech PCL ranks #668 out of 1961 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's EV-to-Revenue compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, DOD Biotech PCL ranks #668 out of 1961 companies for EV-to-Revenue. This puts DOD Biotech PCL in the upper half of its industry. The industry median EV-to-Revenue is 1.08. DOD Biotech PCL's value of 0.74 is 31.5% below this benchmark. Historically, DOD Biotech PCL's own EV-to-Revenue has ranged from 0.55 to 12.56 over the past decade. While the company's 10-year median is 3.33 vs. the industry median of 1.08, DOD Biotech PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Consumer Packaged Goods company?
The median EV-to-Revenue among Consumer Packaged Goods companies is 1.08, based on 1,961 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DOD Biotech PCL's current EV-to-Revenue of 0.74 is 31.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on DOD Biotech PCL and its competitors. For the Consumer Packaged Goods industry, the median EV-to-Revenue is 1.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DOD Biotech PCL's current EV-to-Revenue is 0.74, which is 78% below median its own 10-year median of 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current EV-to-Revenue of 0.74. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current EV-to-Revenue is 0.74, which is 78% below median its 10-year median of 3.33 and 31.5% below the Consumer Packaged Goods industry median of 1.08. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current EV-to-Revenue is 0.74 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?
Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued.
The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.
Key valuation signals for BKK:DOD-R:
EV-to-Revenue: 0.74 (78% below median its 10-year median of 3.33)
GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
Industry Position: 31.5% below the Consumer Packaged Goods median (#668 of 1961)
No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score
Get the complete analysis for BKK:DOD-R
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:DOD-R has been successfully added to your 
